ALNYLAM PHARMACEUTICALS, INC.
About ALNYLAM PHARMACEUTICALS, INC.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $3.7B
- Net income
- $313.7M
- Total assets
- $5.0B
- Market cap
- $40.5B
- Gross margin
- 81.8%
- Operating margin
- 13.5%
- Net margin
- 8.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.7B
- Cost of revenue
- $677.2M
- Gross profit
- $3.0B
- Operating expenses
- $2.5B
- Operating income
- $501.6M
- Income tax
- $9.4M
- Net income
- $313.7M
- EPS (basic)
- $2.39
- EPS (diluted)
- $2.33
Balance sheet
- Total assets
- $5.0B
- Current assets
- $4.1B
- Total liabilities
- $4.2B
- Current liabilities
- $1.5B
- Shareholders’ equity
- $789.2M
Cash flow
- Operating cash flow
- $524.1M
- Investing cash flow
- $436.3M
- Financing cash flow
- -$305.2M
- Net cash flow
- $690.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $40.5B
- P/E ratio
- 125.4
- EPS (diluted)
- $2.33
- Shares outstanding
- 138.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 28, 2004
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $313.7M in FY2025.
- Revenue grew 340% from FY2021 to FY2025.
- Gross margin of 81.8%, net margin 8.4%.
- Trading 41% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 125.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ALNYLAM PHARMACEUTICALS, INC..
Write a review
News about ALNYLAM PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
